Campath/MabCampath (Sanofi/Genzyme) withdraws marketing in EU and US for oncology indications. - 22-Aug-2012

Sanofi/Genzyme have withdrawn MabCampath (alemtuzumab) from the European market and established a free distribution programme for B-cell CLL users. In the United States the FDA licence will be maintained but a free Campath Distribution Program will offer the drug freely to patients. The intention is to avoid confusion between Campath/MabCampath and the newly developed version of alemtuzumab for which Sanofi/Genzyme is seeking approval in the US and EU as Lemtrada for the treatment of Multiple Sclerosis and to avoid off-label prescribing of the oncologic version to Multiple Sclerosis patients when it is finally approved.

Related News

Phase II data shows PCI 32765 (Pharmacyclics Inc.) provides sustained control in CLL patients

Obinutuzumab (Genentech) success in Phase III trial for CLL

Phase III trial success for PCI 32765 (Janssen Biotech) in CLL treatment

Campath/MabCampath (Sanofi/Genzyme) withdraws marketing in EU and US for oncology indications.

MabCampath/Campath plus fludarabine offers improved treatment for CLL

Barrx RF Ablation system success in Barrett's Oesophagus

Study shows NeuroStar TMS (Neuronetics) successful for patients with Depression

Phase III study of USL 255 (Upsher Smith Labs) shows success for Epilepsy treatment

Related Oncology Information

View all

Oncology Clinical Guidelines

Familial breast cancer: The classification and care of women at risk of familial breast cancer in primary, secondary and tertiary care

NICE

Prostate cancer: diagnosis and treatment

NICE
View all

Oncology Clinical Trials

Multi-Center Randomized Clinical Trial Irreversible Electroporation for the Ablation of Localized Prostate Cancer

Clinicaltrials.gov 08 April 2013

Pancreatic Carcinoma: Chemoradiation Compared With Chemotherapy Alone After Induction Chemotherapy (CONKO-007)

Clinicaltrials.gov 04 April 2013
View all

Oncology Medical Journal Abstracts

Bone mass density, fracture history, self-reported osteoporosis as proxy variables for estrogen and the risk of non-small-cell lung cancer—A population based cohort study, the HUNT study: Are proxy variables friends or faults?

Lung Cancer 24 April 2013

Prognostic value of K-RAS mutations in patients with non-small cell lung cancer: A systematic review with meta-analysis

Lung Cancer 22 April 2013
View all

Oncology Medical Apps

CCO Oncology inPractice

Free

Cancer Signs and Symptoms

Free

Related Oncology Drugs

Back to top
View all

Latest News

Takeda acquires vaccine maker Inviragen

10 May 2015

Takeda Pharmaceutical Company Limited and Inviragen, Inc. jointly announced that Takeda, its wholly owned subsidiary Takeda America...

Read full article

Barrx RF Ablation system success in Barrett's Oesophagus

24 May 2013

Covieden has announced that results from a prospective, multicenter, randomized, controlled clinical trial (The SURF Trial -SUrveillance vs....

Read full article

Study shows NeuroStar TMS (Neuronetics) successful for patients with Depression

24 May 2013

New data show that the NeuroStar TMS Therapy System, from Neuronetics, induced statistically and clinically meaningful response and...

Read full article